RedHill Biopharma Provides 2017 Semi-Annual Business Update

TEL-AVIV, Israel, Jan. 13, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today provided an update on key programs, potential milestones and estimated timelines.

Micha Ben Chorin, RedHill’s CFO, said: “We are heading into 2017 with important potential catalysts in the coming months and with several ongoing Phase III and Phase II programs for gastrointestinal indications. Following the recently announced U.S. co-promotion agreement for Donnatal®1, RedHill is advancing its strategic transition into a revenue-generating, gastrointestinal-focused, specialty pharmaceutical company with commercial presence in the U.S. This transition is planned to support potential future commercialization of RedHill’s Phase III-stage gastrointestinal drugs, if approved by the FDA. We are backed by strong institutional investors and maintain a debt-free balance sheet with approximately $70 million in cash, allowing us to continue to diligently execute our plans.”


SOURCE : RedHill Biopharma Ltd. 

Need For Smart, Creative Strategy To Draw Youngsters To Islamic Teachings

KUALA LUMPUR, Jan 12 (Bernama) -- Religious institutions need to employ a smart and creative strategy in line with the needs of young people in bringing them closer to Islamic teachings.

Institute of Islamic Understanding Malaysia (IKIM) director-general, Prof Datuk Dr Azizan Baharuddin said with the world becoming increasingly challenging now, creativity in doing missionary work was important to ensure that Islamic teachings could be delivered effectively.

--BERNAMA

http://www.bernama.com/bernama/v8/newsindex.php?id=1319366

CUMMINS INC. DOES NOT USE DEFEAT DEVICES AND IS COMMITTED TO MEETING EMISSIONS STANDARDS

Cummins Does Not Supply Engines for the FCA Products in Question

COLUMBUS, Ind., Jan 13 (Bernama-BUSINESS WIRE) -- Cummins Inc. (NYSE: CMI) today stated that it does not supply engines for the FCA vehicles that are discussed in the Environmental Protection Agency's Notice of Violation issued today, nor was Cummins named.

http://mrem.bernama.com/viewsm.php?idm=28269

PWC ANNOUNCES NEW GLOBAL CORPORATE TAX SERVICES TEAM

Global Enterprise Tax Solutions Team Comprised of Former GE Tax Group

NEW YORK, Jan 13 (Bernama-BUSINESS WIRE) -- Today, PwC announced an innovative agreement with GE to provide integrated, enterprise managed tax services to GE on a global basis. As part of this agreement, PwC will hire more than 600 of GE's highly regarded tax team members from around the world and acquire GE's tax technologies to further both PwC's focus on the Tax Function of The Future and the provision of global enterprise tax solutions to the marketplace.

PwC has the largest tax practice in the US and the world with a global network of 41,000 tax professionals operating in 157 countries. Leveraging the proven experience and expertise of the GE team, PwC believes it has identified an opportunity that recognizes the future needs of a rapidly changing marketplace.

http://mrem.bernama.com/viewsm.php?idm=28267

RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections

TEL-AVIV, Israel, Jan. 12, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that RHB-104 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA for the treatment of Nontuberculous Mycobacteria (NTM) infections. The QIDP designation was granted under the FDA's Generating Antibiotic Incentives Now (GAIN) Act, which is intended to encourage development of new antibiotic drugs for the treatment of serious or life-threatening infections.

The granted QIDP designation allows RedHill to benefit from Fast-Track status, with an expedited development pathway for RHB-104 for the treatment of NTM infections, as well as Priority Review, which provides for a shorter review time by the FDA of a future potential marketing application. If approved for the treatment of NTM infections, RHB-104 would also receive an additional five years of U.S. market exclusivity on top of the standard exclusivity period.     

RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties. 

COLLIERS INTERNATIONAL EXPANDS IN DENMARK

Acquires market-leading Colliers Denmark affiliate to strengthen global platform

TORONTO, Jan 13 (Bernama-GLOBE NEWSWIRE) -- Leading global commercial real estate services firm Colliers International Group Inc. (NASDAQ:CIGI) (TSX:CIGI) announced today that it has acquired a controlling interest in Colliers International Denmark (“Colliers Denmark”). Senior management of Colliers Denmark will retain the balance of the equity under Colliers International’s unique enterprise partnership model. The acquisition of Colliers Denmark further strengthens Colliers International’s operations in Europe and provides a strong platform for future growth in the important Nordic region. The terms of the transactions were not disclosed.

http://mrem.bernama.com/viewsm.php?idm=28268

TOSHIBA LAUNCHES SECOND GENERATION 650V SIC SCHOTTKY BARRIER DIODES WITH IMPROVED SURGE FORWARD CURRENT

TOKYO, Jan 12 (Bernama-BUSINESS WIRE) -- Toshiba Corporation’s (TOKYO:6502) Storage & Electronic Devices Solutions Company today announced the launch of second generation 650V silicon carbide (SiC) schottky barrier diodes (SBDs) that improve on the surge forward current (IFSM) offered by the company’s current products by approximately 70%. Shipments of the new line-up of eight SiC schottky barrier diodes start today.

The new SiC schottky barrier diodes, fabricated with Toshiba’s second-generation SiC process, deliver approximately 70% better surge forward current than first generation products, and at the same time reduce the switching loss index of “RON * Qc” [1] by around 30%, making them suitable for use in efficient power factor correction (PFC) schemes.

http://mrem.bernama.com/viewsm.php?idm=28266